We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards (EW) Rides on Innovation Despite Regulatory Issues
Read MoreHide Full Article
On Dec 26, we issued an updated research report on Edwards Lifesciences Corporation (EW - Free Report) . The hugely untapped potential in the emerging markets aids the company. However, reimbursement issue deters growth. The stock currently has a Zacks Rank #3 (Hold).
Shares of this manufacturer of tissue heart valves and repair products used for replacing or repairing a patient's diseased or defective heart valve have outperformed its industry over the past six months. The stock has rallied 27.1% compared with the 6% rise of the industry.
Edwards Lifesciences has been seeing strong transcatheter valve sales in the domestic and overseas markets. In the last reported quarter, the company registered solid sales within its Critical Care division, driven by robust HemoSphere sales, primarily in the United States and Europe. The HemoSphere all-in-one monitoring platform (with FloTrac System and Acumen Hypotension Predictive Index) is gaining momentum from its sturdy rollout earlier this year, which saw a full-market launch.
The company is upbeat about getting enormous synergy benefits from its CASMED acquisition (completed in April). The buyout is fortifying Edwards Lifesciences’ position in smart monitoring technologies within the critical care platform. In Transcatheter Mitral and Tricuspid Therapies (TMTT), following the CE Mark, PASCAL is currently witnessing a powerful rollout in Europe.
Within Surgical Structural Heart, Edwards Lifesciences registered firm underlying growth on continued adoption of its high-value technologies and progress outside the United States. The company is currently witnessing a steady uptake of INSPIRIS RESILIA tissue valves across all regions, driven by increased demand among younger and more active patients.
However, spending on new European device regulations and manufacturing variances proved to be dampeners. This apart, a tough competition in the cardiac devices market is concerning.
Key Picks
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and NuVasive, Inc .
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank of 2.
NuVasive’s long-term earnings growth rate is anticipated at 12.9%. It is currently a Zacks #2 Ranked player.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Edwards (EW) Rides on Innovation Despite Regulatory Issues
On Dec 26, we issued an updated research report on Edwards Lifesciences Corporation (EW - Free Report) . The hugely untapped potential in the emerging markets aids the company. However, reimbursement issue deters growth. The stock currently has a Zacks Rank #3 (Hold).
Shares of this manufacturer of tissue heart valves and repair products used for replacing or repairing a patient's diseased or defective heart valve have outperformed its industry over the past six months. The stock has rallied 27.1% compared with the 6% rise of the industry.
Edwards Lifesciences has been seeing strong transcatheter valve sales in the domestic and overseas markets. In the last reported quarter, the company registered solid sales within its Critical Care division, driven by robust HemoSphere sales, primarily in the United States and Europe. The HemoSphere all-in-one monitoring platform (with FloTrac System and Acumen Hypotension Predictive Index) is gaining momentum from its sturdy rollout earlier this year, which saw a full-market launch.
Edwards Lifesciences Corporation Price
Edwards Lifesciences Corporation price | Edwards Lifesciences Corporation Quote
The company is upbeat about getting enormous synergy benefits from its CASMED acquisition (completed in April). The buyout is fortifying Edwards Lifesciences’ position in smart monitoring technologies within the critical care platform. In Transcatheter Mitral and Tricuspid Therapies (TMTT), following the CE Mark, PASCAL is currently witnessing a powerful rollout in Europe.
Within Surgical Structural Heart, Edwards Lifesciences registered firm underlying growth on continued adoption of its high-value technologies and progress outside the United States. The company is currently witnessing a steady uptake of INSPIRIS RESILIA tissue valves across all regions, driven by increased demand among younger and more active patients.
However, spending on new European device regulations and manufacturing variances proved to be dampeners. This apart, a tough competition in the cardiac devices market is concerning.
Key Picks
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and NuVasive, Inc .
Haemonetics has a Zacks Rank #2 (Buy) and a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank of 2.
NuVasive’s long-term earnings growth rate is anticipated at 12.9%. It is currently a Zacks #2 Ranked player.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>